Long-term comparison and performance study of consumer grade electronic radon integrating monitors.

This study reports the performance of 7 types of consumer grade passive Electronic Radon Integrating Monitors, ERIM (AlphaE, AER Plus, Canary, Corentium Pro, Radon Scout Home, Ramon and Wave) and passive etched track radon detectors. All monitors and passive radon detectors were exposed side by side for 2 periods of 3 months under controlled conditions in the UKHSA radon chamber and in a stainless steel container to an average radon concentration of 4781 Bq m-3 and 166 Bq m-3, respectively. The performance of each individual monitor was compared with Atmos 12DPX and AlphaGUARD P30 reference instruments. The performance of the monitors was evaluated by estimating the biased, precision and measurement errors of each type. It was found that UKHSA passive radon detectors showed excellent performance (measurement error < 10%) at both higher and lower exposures. The AlphaE, Canary and Ramon showed excellent performance, with measurement error < 10%, when they were exposed to radon concentrations between 4000 Bq m-3 and 6000 Bq m-3 in the UKHSA radon chamber. However, when the monitors were exposed to radon levels below the UK radon Action Level of 200 Bq m-3, the only ERIM which had a measurement error <10% was the Radon Scout Home. All other monitors showed a significant decrease in their performance with measurement errors ranging between 20% and 50%. The calibration factor, which is the ratio between the measured value (background is subtracted) and the reference value, was also studied. It was found that the calibration factors of individual monitors changed significantly. Calibration measurements in 2019 and in 2023 found that the percentage change varied between -46% and +63%. This shows the importance of initial and regular calibration, and maintenance of the monitors. .

RADON BASELINE MONITORING AROUND A POTENTIAL SHALE GAS DEVELOPMENT SITE IN YORKSHIRE, ENGLAND.

The Vale of Pickering in Yorkshire, England has been identified as a potential area for shale gas extraction. Public Health England joined a collaboration led by the British Geological Survey for environmental baseline monitoring near the potential shale gas extraction site following a grant award from UK Government Department for Business, Energy and Industrial Strategy. The analysis of results for the first 6 months of indoor monitoring indicated that the results followed a log-normal distribution. The numbers of homes found to be at or above the Action Level followed the numbers predicted by the radon potential maps. The results from the measurements of outdoor air in this study indicated that the radon concentrations are slightly higher than previously measured but close to the detection limit of the technique.

Seasonal variation of radon concentrations in UK homes.

The patterns of seasonal variation of radon concentrations were measured in 91 homes in five regions of the UK over a period of two years. The results showed that there was no significant difference between the regions in the pattern or magnitude of seasonal variation in radon concentrations. The arithmetic mean variation was found to be close to that found previously in the UK national survey. Differences in the pattern between the two years of the study were not significant. Two-thirds of homes in the study followed the expected pattern of high radon in the winter and low radon in the summer. Most of the rest showed little seasonal variation, and a few showed a reversed seasonal pattern. The study does not provide any clear evidence for the recorded house characteristics having an effect on the seasonal variation in radon concentrations in UK homes, though the statistical power for determining such effects is limited in this study. The magnitude of the seasonal variation varied widely between homes. Analysis of the individual results from the homes showed that because of the wide variation in the amount of seasonal variation, applying seasonal correction factors to the results of three-month measurements can yield only relatively small improvements in the accuracy of estimates of annual mean concentrations.

Radon activity concentration--a Euromet and BIPM supplementary comparison.

For the first time, a comparison of radon activity concentration in air has been performed within the scope of Euromet. In the project 657, 'Comparison of calibration facilities for the radon activity concentration,' 12 participants from 9 countries compared different radon reference atmospheres at 1, 3 and 10 k Bq m-3 via a transfer standard. The comparison was listed as BIPM supplementary comparison EUROMET.RI(II)-S1. The results of most participants are correlated due to common traceability to one single radon gas standard producer. This makes a careful correlation analysis necessary to achieve an appropriate comparison reference value. The results of the comparison as well as the complex analysis of the correlated set of data is presented and discussed.

Practical procedures for a radon etched track dosimetry service.

Etched track detectors are widely used for the detection of radon and its decay products. They have many desirable attributes: they are small, cheap, simple, non-toxic and non-hazardous. Etched track detectors provide adequate accuracy for most radiological protection purposes provided stringent quality assurance is maintained. The UK validation scheme provides an important component of QA but continuous monitoring of conditions and results is also needed. If these conditions are observed, these detectors provide an entirely adequate tool for large-scale use in assessing levels of radon in houses. Accurate estimates of long-term average radon levels require a measurement over several months because of the short-term fluctuations in radon concentrations.

Treatment of nasopharyngeal carcinoma with human leukocyte interferon.

Nasopharyngeal carcinoma (NPC) is a human neoplasm closely associated with Epstein-Barr virus (EBV). Human leukocyte interferon (IFN) has known antiviral and antineoplastic properties. After initial IFN treatment in one NPC patient demonstrated acceptably low toxicity, 12 additional patients were treated on a protocol with IFN, 10 X 10(6) units intramuscularly (IM) daily for 30 days. IFN did not affect serum anti-EBV antibody titers (IgA and IgG antiviral capsid and early antigens). Of six patients tested, none was found to excrete EBV in saliva before, during, or after IFN. Four patients had measurable tumor regression (two partial responses and two minor responses), three had stable disease, and five patients plus the initial preprotocol patient had progressive disease. Toxicity included fever, fatigue, and myalgias in all patients, thrombocytopenia in two patients, and neutropenia in three patients. Three patients were withdrawn from the study, one each for severe fatigue, neutropenia, and hypotension. This study demonstrates that IFN has sufficient activity in advanced NPC to justify further investigation.

Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.

In a phase II trial, cisplatin was given by two randomly assigned dose schedules to 53 children with malignant solid tumors. Both schedules, 30 mg/m2/week and 90 mg/m2 every 3 weeks, were associated with drug-related toxic effects involving the renal, hematopoietic, and neuromuscular systems. Pharmacokinetic studies indicated that the initial serum half-life of total platinum was 27.6 minutes, with a terminal half-life of 44.4 hours. Significant antitumor effect was noted in patients with neuroblastoma and malignant germ cell tumors. Use of cisplatin in combination therapy for patients with these diseases is indicated.

Malignant germ cell tumors in 57 children and adolescents.

Fifty-seven patients with malignant germ cell tumors (GCTs) treated at our center between 1962 and 1979 were evaluated to determine 1) the prognostic value of disease stage, tumor histology, primary site, and patient age; 2) results of therapy; and 3) patterns of metastasis. The 35 girls and 22 boys were from 1 week to 18 years old (median 5 yr). Primary sites were ovarian (20), testicular (10), sacrococcygeal (12), retroperitoneal (7), mediastinal (5), and other (3). Cox regression analysis indicated that stage was the most important prognostic variable. Extragonadal tumors were usually advanced at diagnosis, but tumor site did not have prognostic value independent of disease stage. Neither patient age nor tumor histology significantly influenced outcome. Drugs active against malignant GCTs included vincristine, cyclophosphamide, and dactinomycin in combination and vinblastine, bleomycin, and cis-platinum. Radiation alone cured nondisseminated germinomas. The most common sites of metastasis were lungs, liver, central nervous system, and bone; other sites were infrequently involved. We conclude that stage was the most important prognostic variable, extragonadal tumors were usually advanced at diagnosis, and similarities in the histogenesis, metastatic pattern, and response to therapy, regardless of primary site, justify the consideration of childhood malignant GCTs as one group.

Treatment of childhood rhabdomyosarcoma at St. Jude Children's Research Hospital, 1962--78.

Between March 1962 and December 1978, 153 children with rhabdomyosarcoma (RMS) received treatment at St. Jude Children's Research Hospital. As of January 1979, 62 of these patients were still alive. Between 1962 and 1968, 20 patients were not treated by protocol, and, between 1968 and 1979, another 13 have been registered as "nonprotocol"; 6 of these 33 patients survive. Since 1968, 120 patients received treatment by 3 stage-related, multiple-modality programs. In the first protocol, chemotherapy consisted of vincristine, cyclophosphamide, and dactinomycin; 14 of 34 patients have survived after 6 to more than 10 years. In the second treatment program, which used adriamycin in addition to the 3 drugs cited above, 20 of 56 subjects remain free of disease after more than 2 to 5.5 years; toxicity of the multiple agents given in combination with radiotherapy proved intolerable and led to a modified 4-agent protocol for patients admitted since early 1977. Of 30 in this latter group, 22 are alive. Forty of 44 patients who remained free of RMS for more than 2 years continue to survive.

Breast metastases in children with rhabdomyosarcoma.

Of 108 consecutively diagnosed patients with rhabdomyosarcoma, seven subsequently developed clinically evident metastatic tumors of the breast. These patients were unusual in that all had primary tumors located on an extremity or the buttock, and six of the seven tumors had alveolar histology. Sex distribution and age of the patients indicated that the physiologic state of the breast was an important determining factor in the development of such metastases.

Retroperitoneal rhabdomyosarcoma in children. Results of multimodality therapy.

The clinical course of 18 consecutive children treated for primary retroperitoneal rhabdomyosarcoma was reviewed. At diagnosis, 8 patients had regional unresected tumor and 10 patients had disseminated tumor, including 3 patients with documented bone marrow infiltration by tumor. Following combined modality therapy, 14 of 18 patients achieved a greater than 50% tumor response (11 complete and 3 partial responses); 4 patients failed to respond and died of progressive disease within eight months of diagnosis. Among the 14 patients responding, 7 patients had subsequent reextension of active tumor three to 16 months (median, 9 months) following the onset of therapy. Three of the 7 remaining patients died of treatment complications, 2 of intestinal obstruction and 1 of disseminated histoplasmosis, within the first year of therapy and at post-mortem examination had no demonstrable tumor. Four patients are alive and free of active tumor for 10+, 10+, 32+ and 33+ months from diagnosis. Treatment complications have included hematopoietic depression, mucositis, enteritis, intestinal obstruction, excessive weight loss, malnutrition, and life-threatening infection. These results illustrate limitations in current combined modality therapy of retroperitoneal rhabdomyosarcoma and the necessity for future treatment modifications to both reduce morbidity and to improve survival.